Filing Flows › Tela Bio (TELA) › Q1 2026
Tela Bio (TELA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Tela Bio (TELA) reported revenue of $19.1M for the first quarter 2026 (Q1 2026), +3% from a year earlier and -9% from the quarter before. Operating margin was -55.2%, net loss $12.3M (64.4% of revenue).
Tela Bio, Q1 2026: revenue $19.1M (+3% year over year), operating margin -55.2%, net loss $12.3M, operating cash flow −$11.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.1M | -9% | +3% |
| Operating profit | −$10.5M | — | — |
| Net earnings | −$12.3M | — | — |
| Operating cash flow | −$11.2M | — | — |
What changed
Revenue was $19.1M in Q1 2026, up 3% year over year and down 9% from the previous quarter.
Gross margin was 65.7%, down 1.9 points from Q1 2025. Operating costs exceeded revenue by $10.5M, an operating margin of -55.2%. Operating expenses grew 0% against revenue growth of 3%. The quarter ended with a net loss of $12.3M, wider than the previous quarter's $9.0M loss.
Operating cash flow was −$11.2M. Non-cash charges added back $169K of depreciation and $816K of share-based compensation. Capital expenditures of $119K exceeded it, leaving free cash flow of −$11.3M.
Questions
What was Tela Bio's revenue in the first quarter 2026?
Tela Bio (TELA) reported revenue of $19.1M for the first quarter 2026 (Q1 2026), +3% from a year earlier and -9% from the quarter before.
Was Tela Bio profitable in the first quarter 2026?
Operating loss was $10.5M (-55.2% of revenue) and net loss $12.3M.
Source: Tela Bio 10-Q on SEC EDGAR.